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Abstract
Background: Group-based social skills training (SST) has repeatedly been recommended as treatment of choice in
high-functioning autism spectrum disorder (HFASD). To date, no sufficiently powered randomised controlled trial
has been performed to establish efficacy and safety of SST in children and adolescents with HFASD. In this
randomised, multi-centre, controlled trial with 220 children and adolescents with HFASD it is hypothesized, that
add-on group-based SST using the 12 weeks manualised SOSTA–FRA program will result in improved social
responsiveness (measured by the parent rated social responsiveness scale, SRS) compared to treatment as usual
(TAU). It is further expected, that parent and self reported anxiety and depressive symptoms will decline and
pro-social behaviour will increase in the treatment group. A neurophysiological study in the Frankfurt HFASD
subgroup will be performed pre- and post treatment to assess changes in neural function induced by SST versus
TAU.
Methods/design: The SOSTA – net trial is designed as a prospective, randomised, multi-centre, controlled trial with
two parallel groups. The primary outcome is change in SRS score directly after the intervention and at 3 months
follow-up. Several secondary outcome measures are also obtained. The target sample consists of 220 individuals
with ASD, included at the six study centres.
Discussion: This study is currently one of the largest trials on SST in children and adolescents with HFASD
worldwide. Compared to recent randomised controlled studies, our study shows several advantages with regard to
in- and exclusion criteria, study methods, and the therapeutic approach chosen, which can be easily implemented
in non-university-based clinical settings.
Trial registration: ISRCTN94863788 – SOSTA – net: Group-based social skills training in children and adolescents
with high functioning autism spectrum disorder.
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Autism spectrum disorders (ASD) are characterized by
qualitative impairments in social interaction, reciprocal
communication, and by stereotyped, repetitive behaviours.
ASD comprise International Classification of Diseases,
version 10 (ICD-10) diagnoses autism (F84.0), Asperger
syndrome (F84.5), and atypical autism (F84.1), respective
Diagnostic and Statistical Manual of Mental Disorders IV,
text revision (DSM-IV TR) diagnoses autism (299.00),
Asperger’s disorder (299.80) and pervasive developmental
disorder-not otherwise specified (PDD-nos) (299.80).
Recent epidemiological studies estimated a prevalence >
1% for all ASD, with about 45% showing an intelligence
quotient (IQ) > 70 [1,2]. The rate of comorbid psychiatric
disorders, especially attention-deficit/hyperactivity disorder
(ADHD), anxiety and depressive disorders is high [3,4].
The treatment of choice in verbal school-aged children
and adolescents with ASD and language and cognitive
abilities in the average range, referred to as high function-
ing ASD (HFASD), is behaviour-based therapy to improve
communication and social interaction with peers and
adults. Group-based social skills training (SST) has been
advocated as the most efficient treatment option. How-
ever, there is a scarcity of randomised controlled studies
(RCT) implementing treatment manuals [5].
Review articles have delineated the following therapeutic
goals that should be achieved by SST with ASD indivi-
duals [5,6]: increase of social motivation and social initia-
tions, improvement of appropriate social responding,
reduction of interfering behaviours and promotion of skill
generalisation. Effective interventions are predominantly
based on social learning theory, framing complex social
conventions as rules that can be learned by, for example,
modelling age-appropriate social interaction skills or
teaching social scripts for common situations, and succes-
sively practising social interaction within the group by, for
example, role play, video-modelling and direct feedback,
as well as outside the group. In addition, operant methods
as differential reinforcement of response attempts and
positive behaviours are adopted. Some intervention meth-
ods also specifically aim at improving social understand-
ing, emotion recognition, perspective-taking (that is,
theory of mind abilities), and executive functions, as these
aspects are specifically impaired in ASD [7]. As the aspect
of generalisation, that is, the transfer and appropriate use
of an acquired skill in other situations, is crucial for any ef-
fective SST program for children and adolescents with
HFASD, generalisation sessions are added in several inter-
ventions. These can consist of community activities, train-
ing/interacting with typically developing peers, specific
social interaction homework, or change of therapists dur-
ing therapy [6].
Five RCTs in school-age children and adolescents with
HFASD, including at least 10 children in the treatment
group and implementing manualised training have been
published to date [8-12]. A summary of the study char-
acteristics, inclusion criteria and outcome measures are
shown in Table 1. All studies were performed with chil-
dren aged 7 to 12 years old; none included adolescent
children. The studies differ considerably with respect to
inclusion criteria, randomisation procedure (often not
reported), kind and duration of the intervention, and
outcome measures.
One study implemented a very intensive summer
treatment programme over 5 weeks [12], and one was
based within school settings [10]. One study aimed at
targeting individual child-specific aims within a group-
based setting [11]. The two remaining studies used the
classical format of highly structured social skills training
with weekly sessions for the children and additional par-
ent training sessions of varying intensity [8,9].
With respect to inclusion criteria, both latter studies
only included children with IQ > 85, whereas the other
studies also included less cognitively able children with
IQ > 60 or IQ > 70. Most studies did not report specific
inclusion or exclusion criteria apart from the diagnosis
of ASD, which, however, was not specifically confirmed
by a standardised assessment prior to start of therapy in
all studies. As ASD are heterogeneous disorders with a
high rate of psychiatric and medical comorbidity and a
variable course, not reporting standardised diagnostic as-
sessment of ASD before start of the intervention, and not
reporting psychiatric respective medical comorbid disor-
ders are strong limitations of the published studies. In
addition, only one study mentioned the use of psycho-
tropic medication as an exclusion criterion [10], whereas
the other studies did not report any information on the
use of psychotropic medication. As the additional use of
psychotropic medication is a major possible confounding
factor, this is another limitation of most studies.
With respect to outcome measures, all studies imple-
mented different parent rating scales for assessing social
skills, which showed a positive effect of the respective
training in all studies. Most studies did not report a pri-
mary outcome measure, but used several outcomes sim-
ultaneously. Effect sizes were not reported in all studies,
and the long-term effect after 3 or 5 months of therapy
was only assessed in two studies [8,10]. Where reported,
effect sizes differed strongly by outcome measure be-
tween small and large effects. A few studies implemen-
ted child-based measures, which showed less strong or
no effects compared to parent ratings.
Taken together, the previous randomised controlled
studies on social skills training showed a medium to
large effect on parent-reported social skills in children
with ASD directly after the end of therapy, but suffer
from several methodological and practical limitations.
Thus, the present SOSTA-net trial aimed at overcoming
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http://www.trialsjournal.com/content/14/1/6Table 1 Characteristics of published randomised controlled trials on social skills training in high-functioning autism spectrum disorder (HFASD)
Publication /
comparison groups
Inclusion / exclusion criteria Subjects, number;
age; RP
Intervention Manual Outcome measures
pre/post treatment
Results
pre/post
treatment
Effect size
group x
time #
Beaumont and
Sofronoff, 2008, Junior
Detective Training
Program / treatment
versus wait-list control
condition
Asperger syndrome; IQ > 85;
no exclusion criteria reported
N = 49; 7.5-11 years;
RP not described
4-weekly computer game training sessions
(child and parents, 45 minutes) plus
8-weekly group therapy sessions with
global targets (2 therapists / 3 children,
75 minutes); parallel 8-weekly parent
trainings; teacher handouts
Yes No primary outcome measure
SSQ-P (PR) P < 0.001 η
2 = 0.37
ERSSQ-P (PR) P < 0.001
Child measures:
Emotion recognition ns
Knowledge of emotion
management strategies
P < 0.001
Treatment effect was maintained
for 5 months (parent ratings)
DeRosier et al., 2011
S.S.GRIN-HFA /
treatment versus
traditional S.S.GRIN
Autism, Asperger syndrome,
PDD-nos; IQ > 85;
exclusion of children with
CBCL-aggression subscale > 70
N = 55; 8-12 years;
RP not described
S.S.GRIN-HFA: 15 group sessions of 60
minutes, and 4 parent training sessions;
traditional S.S.GRIN: 10 group sessions of
60 minutes (2 therapists/group)
Yes No primary outcome measure
Parent report: SRS – subscales P < 0.05 d: 0.68 - 0.94
ALQ P < 0.05 d = 0.75
Child report:
Social dissatisfaction
questionnaire
ns
Social self-efficacy scale ns
Frankel et al., 2010
Children’s Friendship
Training” / treatment
versus wait-list control
condition
Autism spectrum disorder
(ADI-R, ADOS); verbal IQ > 60;
child has to be able to switch
topics in conversation and
knows several play rules;
attending regular classroom
without individual support;
exclusion criteria: psychotropic
medication; neurological or
medical disorder
N = 76 randomised,
n = 68 completed
training (58 boys,
10 girls); 7 - 12 years;
RP: random.org
12 weeks of CFT within classes conducted
by the UCLA friendship program;
12 session of 60 minutes for the child;
12 parallel sessions of 60 minutes for
parents parents support homework and
generalisation (i.e. arranging play dates)
Yes No primary outcome measure
Child report:
The loneliness scale P < 0.025
Piers-Harris self-concept scale P < 0.025
parent report: 2
subscales
P < 0.001 QPQ-P (5 subscales)
SSRS (4 subscales) 1 subscale
P < 0.05
Teacher report: PEI
treatment effect was
maintained for 3 months
(parent ratings)
ns
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6Table 1 Characteristics of published randomised controlled trials on social skills training in high-functioning autism spectrum disorder (HFASD) (Continued)
Koenig et al., 2010 /
treatment versus
wait-list control
condition
Pervasive developmental
disorder (ADOS, SCQ, PDD-BI)
full scale IQ >= 70;
exclusion criteria: severe
aggressive behaviour, self-
injury, oppositional behaviour
N = 44; 8-11 years (34
boys, 10 girls);
RP: by external faculty
member
16 group therapy sessions of 75 minutes
(2 therapists / 4-5 children, 2 peer tutors);
after 3
rd session: individual treatment plan
for each child (pro-social behavioural
objectives; strategies)
Yes Primary outcome measure: CGI-I P = 0.001
Secondary outcome measure:
Prosocial Index of the Social
Competence Inventory (PR)
ns
Lopata et al., 2010 /
treatment versus wait-
list control condition
Autism, Asperger Syndrome,
PDD-nos IQ > 70, verbal
IQ > 80;
no exclusion criteria reported
N = 36; 7-12 years;
RP not described
Summer training program: 5 weeks with 5
× 70 minutes treatment cycles/day and 3
therapists/6 children; parents: 1/week
parent training of 90 minutes
Yes Set of primary outcome
measures; child measures:
One-tailed
tests
social skills knowledge P < 0.001 d = 1.27
DANVA-2 ns d = 0.53
CASL P < 0.001 d = 0.39
parent ratings:
ASC P = 0.006 d = 0.58
SRS P = 0.003 d = 0.63
BASC-2-PRS: withdrawal P < 0.001 d = 1.06
BASC-2-PRS: social skills ns d = 0.37
ADI-R, Autism Diagnostic Interview-revised; ADOS, Autism Diagnostic Observation Schedule; ALQ, Achieved Learning Questionnaire; ASC, Adapted Skillstreaming Checklist; BASC-2-PRS, Behavior Assessment System for
Children, 2
nd edition, parent rating scales; CASL, Comprehensive Assessment of Spoken Language; CBCL, Child Behavior Checklist; CFT, Children’s Friendship Training; CGI-I, Clinical Global Impressions Scale
Improvement Item; DANVA-2, Diagnostic Analysis of Nonverbal Accuracy 2; ERSSQ, Emotion Regulation and Social Skills Questionnaire; ns, not significant; PDD-nos, Pervasive Developmental Disorder-not otherwise
specified; PDD-BI, Pervasive Developmental Disorders Behaviour Inventory; PEI, The Pupil Evaluation Inventory; PR, parent report; QPQ, Quality of Play Questionnaire; RP, randomisation procedure; SCQ, Social
Communication Questionnaire; SRS, Social Responsiveness Scale; SSQ-P, Social Skills Questionnaire, parent version; SSQ-T, Social Skills Questionnaire, teacher version; SSRS, Social skills rating system; TPSS, Teacher
Perception of Social Skills.
# Effect sizes are shown were reported.
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6several of these limitations by defining clear inclusion
and exclusion criteria, one primary outcome and several
secondary outcome measures assessing immediate and
long-term effects of the therapy after 3 months, using a
specific randomisation procedure, and also including
adolescents and young adults in the trial. In addition,
the large sample size (see below) will also allow the
study of factors influencing therapy outcome, which is
strongly relevant for clinical practice.
The first German group-based social skills training
was developed at the Department of Child and Adoles-
cent Psychiatry at JW Goethe University Hospital,
Frankfurt am Main. A pre-post pilot study showed good
acceptance of the intervention in individuals with
HFASD and their parents, and was effective in improv-
ing social interaction with adults and peers [13]. As this
first SST was designed as ongoing group training, and
therefore did not contain a detailed manual for a limited
number of group therapy sessions, in the current RCT,
the effect of 12 sessions of a revised version, the manua-
lised SOSTA-FRA programme is compared to treatment
as usual (TAU), including wait-list, control condition. It
is hypothesized that social responsiveness in children
and adolescents with HFASD will improve more strongly
with the group-based SOSTA-FRA training than by the
TAU/wait-list.
As the effects of the previous SST studies varied across
and within groups, it also is relevant to explore factors
associated with treatment outcome. Well-established
positive predictive factors are IQ and language ability.
Less well-established influencing factors are severity of aut-
istic symptoms in the three core domains; age, gender, psy-
chiatric comorbid disorders, genetic risk factors, and
medication effects [5,13,14]. These will be assessed in an
exploratory fashion in the present study. In addition, the
effect of SST on underlying brain mechanisms is examined
by the electroencephalographic response to implicit and
explicit facial emotion and biological motion recognition
as correlates of social brain function.
Methods/design
The SOSTA-net trial is designed as a prospective, rando-
mised, controlled, multicentre trial, including an interven-
tion and a waiting-list control group. The intervention
includes 12 highly structured, manualised (SOSTA-FRA
manual), weekly group-based social skills training, each of
90 minutes duration. Five children or adolescents take
part in the intervention group, and the number of skilled
behavioural therapists (that is, those who have studied at
university for a minimum of 5 years and have undergone
> 2 years of additional psychotherapy training) in each
group is two (child-therapist ratio = 5:2). In addition, three
parent training sessions are scheduled at the beginning,
middle and end of the group therapy sessions, both for the
intervention and the control group. The wait-list control
group receives the same social skills training after the end
of trial, that is, after 6 months (3 months intervention and
3 months follow-up).
Objectives and hypothesis
It is hypothesized that add-on group-based SST using
the manualised treatment program SOSTA-FRA will re-
sult in improved social responsiveness and pro-social be-
haviour compared to TAU. The parent-rated Social
Responsiveness Scale (SRS), obtained at baseline, directly
after intervention, and at 3 months follow-up is the pri-
mary outcome measure of interest (see below).
Several additional aspects with regard to secondary
outcome measures will be studied: A second scale, the
Strength and Difficulties Questionnaire (SDQ), assessing
pro-social behaviour, total and peer-related problems,
will be obtained from parents, and improvements in all
three areas are expected. Also, it is expected, that social
responsiveness (SRS), pro-social behaviour, total and
peer-related problems (SDQ) as reported by teachers will
be improved. These are measures of generalisation of
the acquired social skills into the classroom. In addition,
a positive effect on parent- and self-rated anxious and
depressive symptoms is expected.
Variables that could possibly moderate treatment effect,
including age, IQ, sex, comorbid disorders, ASD symptom
severity, medication and common variants of genes related
to social interaction will be explored. Exclusively in Frank-
furt, changes in neural function during perception of so-
cial stimuli, measured by electroencephalograpy (EEG),
will also be assessed pre- and post-therapy and at 3
months follow-up.
Study centres
The trial is performed by close cooperation between six
University Hospital Departments of Child and Adolescent
Psychiatry, Psychosomatics and Psychotherapy in Germany,
which provide a special outpatient service for individuals
with ASD: Aachen, Frankfurt/Main, Homburg/Saar, Köln,
Wuerzburg, and Mannheim. Data management, biometric
support and statistical analyses are provided by the Institute
of Medical Biometry and Informatics (IMBI), University of
Heidelberg. Study monitoring is done by the Coordination
Centre for Clinical Trials (KKS), University of Heidelberg.
Participants‘ inclusion and exclusion criteria
A diagnosis of autism, Asperger syndrome or atypical
autism (ICD-10) is essential to be included in the study.
Diagnostic assessment is standardized according to ICD-
10, by obtaining a detailed medical history, performing
the Autism Diagnostic Interview-Revised (ADI-R), the
Autism Diagnostic Observation Schedule (ADOS), and
a standardized intelligence testing (HAWIK-IV, WIE).
Freitag et al. Trials 2013, 14:6 Page 5 of 12
http://www.trialsjournal.com/content/14/1/6Patients’ incusion and exclusion criteria are listed in
Table 2. Comorbid psychiatric disorders are diagnosed
according to ICD-10 and DSM-IV TR by a German vali-
dated structured interview on psychiatric disorders in
children, the Diagnostic interview on psychiatric disor-
ders in children, German version (Kinder-DIPS) [15].
The sample comprises a group of children and adoles-
cents with high-functioning autism, Asperger Syndrome,
and atypical autism who are typical participants of SST
in ASD. Inclusion and exclusion criteria with regard to
other psychiatric disorders are broad, by only excluding
individuals with schizophrenia, bipolar disorder, social
phobia, obsessive-compulsive disorder, major depressive
disorder with suicidal ideation, or any personality dis-
order as well as aggressive behaviour interfering with
group therapy. This approach reflects the high rate of
comorbid psychiatric disorders in ASD [4], which are
likely to be relevant with respect to therapeutic outcome.
Only disorders which require a more specific and dif-
ferent kind of psychopharmacotherapy and/or psycho-
therapy were excluded as comorbid disorders. Other
frequent comorbid disorders, such as attention-deficit/
hyperactivity disorder or oppositional behaviour as well
as specific phobias or depressive episodes without sui-
cidal ideation, were no reason for exclusion. They will
be assessed in secondary analyses as possible moderating
factors of therapy outcome. Similarly, inclusion criteria
with regard to cognitive abilities were rather broad
allowing children with IQ >=70 into the study. We will
enrol 220 subjects into the clinical trial, that is, 110 sub-
jects per treatment group. Only a single participation in
the trial is allowed.
Criteria for withdrawal
Subjects can withdraw from the trial (1) at their own re-
quest or at the request of the legal representative; (2) if
in the investigator’s opinion continuation of the trial
would be detrimental to the subject’s well-being; (3) on
admission to a psychiatric clinic; (4) if in the investiga-
tor’s opinion the realisation of the program is no longer
possible due to the patient’s behaviour in group therapy
sessions, for example, oppositional or aggressive behav-
iour directed against other group members or herself/
himself. A change in pharmacotherapy is not a criterion
for withdrawal from the trial.
Prior and concomitant treatments
Relevant additional treatments administered to the sub-
jects on entry to the trial or at any time during the trial
are regarded as concomitant treatments und are docu-
mented on the appropriate pages of the case report form
(CRF). TAU is allowed in the intervention as well as the
control group. TAU includes stable psychopharmacother-
apy, stable medication for chronic medical conditions not
interfering with group therapy, individual language, psy-
chomotor or behaviour therapy, personal support at
school or family support. Kind and frequency of TAU in
the treatment and control groups will be compared for
non-random distribution in the statistical analysis.
Psychotropic medication is started or changed at least
four weeks before randomisation and remains stable
(mg/kg body weight) throughout the intervention and
the three months follow-up of the study (with the excep-
tion of dose adjustment to body weight changes). The fol-
lowing psychotropic medication is allowed as single or
combined treatment: SSRI, other antidepressants, typical
or atypical neuroleptics, stimulants, atomoxetine, or mood
stabilisers. In addition, stable medication for the treatment
of chronic conditions such as allergies, asthma, epilepsy,
enuresis, sleeping problems, and intermitting medication
for acute upper respiratory infections and diarrhoea is
allowed. Pharmacological treatment is documented at
Table 2 Inclusion and exclusion criteria of the SOSTA-net trial
Inclusion
criteria
Diagnosis of autism spectrum disorder (ICD-10: F84.0, F84.5, F84.1)
Age 8-20 years at start of group therapy
Informed consent
No, or stable psychopharmacotherapy
Children and parents are fluent in reading German to be able to understand instructions and fill in questionnaires
Exclusion
criteria
IQ < 70 (full scale IQ according to HAWIK-IV/WIE)
Psychiatric disorders: schizophrenia, bipolar disorder, social phobia, obsessive-compulsive disorder, major depressive episode with
suicidal ideation, any personality disorder
Aggressive behaviour interfering with group therapy
Any neurological disorder (exception: well treated epilepsy)
Other medical condition interfering with therapy
Group-based SST during last 6 months prior to the study
Participation in other clinical trials including observation period of competing trials
HAWIK-IV/WIE, Wechsler Scales for children, adolescents and adults with current German norms, measuring IQ; IQ, intelligence quotient.
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tropic medication on treatment outcome will be explored
in the statistical analysis.
Any individual intervention (for example, cognitive be-
havioural therapy, school-based intervention, occupa-
tional, language, psychomotor therapy) or family-based
intervention is also allowed. Any additional treatment is
documented in detail (kind of intervention, dose, fre-
quency, etcetera).
Intervention
SOSTA-FRA is manualised, structured cognitive-behavioural
therapeutic and group-based social skills training for
children and adolescents with ASD. It combines psycho-
educational, experimental, and operant methods of teach-
ing and practising social skills. The groups are lead by two
trained behavioural psychotherapists. Twelve sessions,
each of 90 minutes duration, are provided. Each session
follows a standard sequence of activities: saying hello/
greeting, opening round with group circuit and repetition
of group-rules, session specific topic (which consists of the
introduction of new skills followed by the respective train-
ing), group game, homework and closing round with feed-
back. The following social skills are taught, discussed, and
practised within the 12-week curriculum: establishing
group rules, using eye contact, introducing oneself to
others, awareness and expression of feelings, non-verbal
communication, politeness, listening, getting into contact
with peers, having fun being part of a social group, apo-
logising, conversational skills, negotiation, dealing with
teasing/bullying, making friends, problem solving, self-
regulation, impulse control, and strategies for coping with
anger. Thus, SOSTA-FRA takes on the essential topics
and methods that have been recommended for ASD-
specific SST as delineated in the introduction section
(aiming at increasing social motivation and social initia-
tions, improvement of appropriate social responding, im-
provement of executive functions, reduction of interfering
behaviours and promotion of skill generalisation by social
learning and operant methods, as well as cognitive
approaches). Every session includes homework to ensure
transfer and generalisation of acquired skills. The last ses-
sion includes a group activity outside the clinical setting.
SOSTA-FRA implements a token program for the single
session and for homework, and therapists provide exten-
sive positive reinforcement of response attempts, of appro-
priate responses, and of use of acquired skills.
Accompanying the group-based intervention or during
the waiting time of the control group, three parent train-
ing sessions, each of 90 minutes duration are addition-
ally provided for the intervention and the control group.
The aim of the parent training sessions is to ensure
compliance, educating parents with regard to ASD in a
general way, supporting parents to cope with their
children, increase support between families, giving par-
ents the opportunity to talk about current issues and
aspects of their children, and to obtain the study ques-
tionnaires on a regular basis.
Assessment
The trial time flow is shown in Figure 1. After verifying
the diagnosis of HFASD and screening for eligibility
(T1), ten individuals are included in an age-homogenous
study group. The participants are then randomised to
the intervention and control group, and the baseline as-
sessment (T2) takes place. Following randomisation, the
first parent training (both for parents of the children in
the intervention and the control group) and the first
SST group session of at least five individuals are per-
formed. Mid-intervention assessment takes place after 6
weeks group training, parallel with the second parent
training. This mid-intervention assessment (T3) aims at
obtaining the primary and secondary outcome measures
during the ongoing trial to get some information on
individuals dropping out from the study before T4. One
week after the last group SST session, the third parent
training is provided and post assessment takes place
(T4). To assess the stability of the therapy effects, the
study also includes a follow-up (T5) measurement 3
months after finishing the SST.
Outcome measures
The primary outcome measure is the parent-rated Social
Responsiveness Scale (SRS) which was developed as a
change-sensitive measure of social abilities [16,17]. It
contains 65 items covering social responsiveness and
interaction, communication and stereotyped behaviours
in children and adolescents. Five subscales (social aware-
ness, social cognition, social communication, social mo-
tivation and autistic mannerisms) and a summary score
can be calculated. Change in the total raw score of the
Social Responsiveness Scale (SRS) as assessed by the pri-
mary caretaker (PC) (a) between baseline (T2) and 12
weeks after baseline (T4) (primary endpoint), as well as
(b) between baseline (T2) and 3 months after the end of
the intervention (T5) (co-primary endpoint) is the pri-
mary outcome measure in this study. The parent-rated
SRS has been chosen as the outcome measure in several
studies on SST in HFASD [9,12,14].
The secondary outcome measures aim to differentially
assess aspects of social interaction, psychopathology, de-
pressive and anxious symptoms. All secondary outcome
measures have been validated and are frequently used in
clinical research in child psychology and psychiatry.
Some of these secondary outcome measures have not
been standardized for individuals above 16 or 18 years of
age. However, as changes in raw scores are used as sec-
ondary outcome measures in this study, the reported
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secondary outcome measures will be assessed directly
after therapy and 3 months after the end of intervention:
1. Response to intervention: individual symptom
reduction of at least 16 raw points (1 SD) in
PC-rated SRS total score
2. Teacher (T)-rated SRS (change in total raw score
and response to intervention, that is, reduction of at
least 16 raw points in the T-rated SRS)
3. Change in the SRS subscale raw scores in PC,
T-rated SRS
4. Change in PC-rated anxious-depressive symptoms –
raw score as assessed by the child-behavior checklist
(CBCL). The CBCL is a parent rating scale with 120
Likert (0 to 3)-coded items to assess psychopathology
in different aspects of behaviour [18]. In this study,
the anxious-depressive subscale raw score (14 items)
is chosen, as individuals with HFASD often suffer
from comorbid anxiety and depressive disorder,
Legend
SOSTA-FRA: manualised social skills training
TAU: Treatment as usual
Screening for eligibility
n=300
Compliant individuals meeting eligibility criteria 
with informed consent
n=220
meeting exclusion criteria
no compliance
no informed consent
Baseline assessment and randomization
Week 1: Parent 
Training &
SOSTA-FRA + TAU
n=110
Week 1: Parent 
Training &
TAU
n=110
Week 2-6:
SOSTA-FRA + TAU
Week 2-6:
TAU
Week 7: Parent 
Training &
SOSTA-FRA + TAU
Week 7: Parent 
Training &
TAU
Week 8-12:
SOSTA-FRA + TAU
Week 8-12:
TAU
Week 13:
Parent Training
Week 13:
Parent Training
End of Intervention
3 month after end of intervention
n=103 per group
T1
T2
T3
T4
T5
Assumed dropout
rate = 5%
Figure 1 Trial Time Flow.
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interaction
5. Change in total, pro-social behaviour and peer-
related problems raw scores as assessed by the
Strength and Difficulties Questionnaire (SDQ: PC,
T-rated). The SDQ is a widely used, German-
translated and validated instrument [19] and includes
subscales of conduct, emotional, hyperactivity and
peer-related problems, as well as pro-social
behaviours
6. Change in self-reported depressive symptoms as
assessed by the Depressionsinventar für Kinder und
Jugendliche (DIKJ). The DIKJ is a self-reported scale
for children and adolescents 8 to 16 years of age and
contains 26 Likert (0 to 3)-coded items [20]
7. Qualitative information on motivation and
satisfaction with therapy (self-assessment)
8. assessment of functional genetic variants and
psychotropic medication as possible moderating
variables of therapeutic effect;
9. change in electrophysiological brain activation during
the processing of social stimuli. EEG based evoked
potentials to emotional faces and Mu oscillations to
biological motion patterns to study neural change
induced by SST are obtained at T2, T4 and T5 at the
Frankfurt study site, aiming at including 25 HFASD
individuals from the treatment and 25 HFASD from
the control group.
Sample size calculation
The sample size calculation refers to the primary end-
point, change in SRS total score between baseline and
12 weeks after baseline, in the ITT population. The prior
assumption for the treatment effect of the experimental
intervention is based on the results of Tse et al. (2007)
with a treatment mean difference of 11 points and SD of
28 points. It is assumed that the mean SRS total score
does not change for the control group and that the same
SD as in the experimental intervention holds true. With
a two-sided significance level of α = 5% and a power of
1-β = 80%, a sample size of 206 (2 × 103) is required to
detect this difference with a two-sample t-test. It can be
expected that application of an analysis of covariance as
defined for the evaluation (see below) will reduce the
SD, thus increasing the actual power of the study. Based
on the observations made in the study of Tse et al.
(2007), the dropout rate during the intervention is
assumed to be about 5%. Therefore, 220 individuals will
be randomised in total, to obtain at least 206 evaluable
patients. On the basis of the information from the clin-
ical study centres, it is expected that about 25% of the
screened patients cannot be included in the study due to
violation of the inclusion/exclusion criteria. Hence, 300
patients will be assessed for eligibility. Sample size calcu-
lation was done using nQuery Advisor 7.0 [21].
Methods against bias
To randomly allocate influencing factors and to avoid se-
lection bias, patients are randomly assigned by centralised
randomisation to each group (intervention group and
wait-list/TAU control group). An internet-based random-
isation system (http://randomizer.at) is used. The random-
isation is done in an allocation ratio of 1:1 with variable
block length and is stratified for each participating centre.
To ensure that all participating centres will implement
the SST and parent training in a very comparable way
across centres, all therapists are trained in the SOSTA-
FRA program before the beginning of the study in their
centre. Further, all therapists are supplied with a detailed
written manual including all performance rules. Regular
telephone supervision and meetings are provided. In
addition, one therapy session of each intervention group
is videotaped and analysed for compliance with the man-
ual by independent raters at the Frankfurt study centre.
Reliability training in diagnostic measures has been per-
formed before the start of the study.
As the proposed study is a behavioural therapy inter-
vention study, blinding of participants as well as thera-
pists or parents is not possible. Teachers are blinded to
intervention. Therefore, a possible bias of the SRS-
parent scores can be detected by comparing it to the
SRS-teacher scores. The teacher scores, however, will
not be used as primary outcome measure, as it is to be
expected from previous studies [22] that return of
teacher questionnaires will only be around 50 to 60%.
Independent clinical on-site monitoring to ensure pa-
tient safety and integrity of the clinical data in adherence
to the study protocol focuses on source data documenta-
tion, correctness of data, and adherence to trial proce-
dures, for example, randomisation and treatment.
Statistical analysis
Confirmatory analysis is performed for the ITT popula-
tion, and is defined on the basis of the ITT principle. An
additional per-protocol analysis will be conducted, which
will include all patients without major protocol viola-
tions. Two primary endpoints are assessed in confirma-
tory analysis, namely the change in SRS total score
between baseline and 12 weeks after baseline (effect at
the end of therapy) and the change in SRS total score
between baseline and three months after the end of ther-
apy (maintenance effect). To ensure control of the mul-
tiple type I error rate at 5%, a hierarchical test procedure
will be applied [23]: The first null hypothesis to be tested
states that the change in SRS total score between base-
line and 12 weeks after baseline is equal for both groups.
If this hypothesis can be rejected at the two-sided
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that the change in SRS total score between baseline and
three months after the intervention is equal in both
groups is tested at the two-sided level 5%. If the first null
hypothesis cannot be rejected, the second null hypothesis
referring to the co-primary endpoint is also accepted.
Both null hypotheses will be tested by analysis of co-
variance with the covariates baseline SRS total score,
age, IQ, and centre. Gender and medication effects were
not observed in previous studies [14], and hence these
variables are not included in the model of the primary
analysis. Missing values with respect to post-baseline
primary outcomes will be handled by application of the
mixed-effects model for repeated measures (MMRM)
approach that turned out to show favourable character-
istics in terms of the type I error rate, power, and bias of
estimates as compared to alternative methods dealing
with missing values, such as last-observation-carried-for-
ward (LOCF) [24-26].
Descriptive methods will be used for the analysis of
the secondary outcomes, including calculation of appro-
priate summary measures of the empirical distribution
as well as calculation of descriptive two-sided P-values.
A special focus of the exploratory analysis will be with
respect to the time course of the primary as well as the
secondary endpoints. Additionally, sensitivity analyses
will be conducted for different populations (per-protocol
population, appropriate subgroups) and applying alterna-
tive imputation techniques (such as LOCF) for missing
values. Further exploratory analyses will be performed to
identify intervention effects in subgroups and potential
prognostic factors (including genetic variants) for an
intervention effect. Graphical methods will be applied to
visualise the findings of the study. The safety analysis
includes calculation and comparison of frequencies and
rates of adverse and serious adverse events (SAEs)
reported in the two intervention groups. All analyses will
be done using the latest SAS version (9.1 or higher).
Safety aspects
An independent Data and Safety Monitoring Board
(DSMB) is established, involving two independent clin-
ical experts and one biometrician for monitoring the
progress of the trial and ensure adherence to protocol.
Safety parameters are all SAEs and adverse events (AEs)
reported by the subject or PC, or detected by the local
investigator, that occur during and up to three months
after treatment. All noticeable problems must be docu-
mented in the CRF. Even though the character of the
intervention as a behavioural therapy makes SAEs ex-
tremely unlikely, the Ethics Committee and DSMB will
be informed in the case of SAEs within 24 hours after
the SAE becomes known.
Ethical issues
The procedures set out in the trial protocol pertaining
to conduct, evaluation and documentation of this trial is
designed to ensure that all persons involved in the trial
comply with Good Clinical Practice (GCP) and the eth-
ical principles described in the latest accepted version of
the Declaration of Helsinki in Germany. The trial is car-
ried out in keeping with local legal and regulatory
requirements, although German Drug Law (AMG) and
Medical Device Law (MPG) are not applicable. Each
site’s principal investigator ensures that all persons
assisting with the trial are adequately informed about
the protocol, any amendments to the protocol, the trial
treatments, and their trial-related duties and functions.
Before the first subject has been enrolled, all ethical and
legal requirements have been met. Study protocol, patient
information and the respective consent form were approved
by the responsible Ethical Committees before the start of
the trial. The study protocol was first ethically reviewed by
the ethical committee of the Medical Faculty, Goethe
Universität, Frankfurt am Main, Germany, on 30 March
2010 (No. 57/10). Subsequent approval of this vote was
done by the ethical committees of the Medical Faculties in
Aachen (27 August 2010), Köln (1 September 2010),
Mannheim (7 September 2010), Würzburg (25 October
2010), and the Ärztekammer des Saarlandes, Germany (26
May 2010). Parents and participants are informed indi-
vidually about the study and need to consent separately to
the three parts of the study (intervention, genetics, and
neurophysiology). Participants are allowed to take part
only in the intervention study if they do not agree to the
genetic or neurophysiological part of the study. Through-
out the trial, subjects are pseudonymised. Authorized per-
sons (clinical monitors) regularly control adherence to
protocol. During on-site visits, they inspect subject-related
data to ensure adherence to data protection laws and cor-
rectness and completeness of data. As TAU is allowed for
the treatment and the control group, and as the control
group can take part in the training after completion of the
trial, the treatment and control group experience no dis-
advantage related to clinical intervention by taking part in
the trial.
Discussion
This study is currently one of the largest trials world-
wide on SST in children and adolescents with HFASD.
When the study was planned in 2008, no RCTs on SST
in HFASD had been published in an English, or German,
scientific peer-reviewed journal. Since then, the studies
shown in Table 1 have been published. Compared to
these studies, our study shows several advantages with
regard to the following aspects: (1) sample with specific
inclusion and exclusion criteria; (2) study methods; and
(3) therapeutic approach.
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tic criteria for ASD are obtained by standardised instru-
ments, but also an additional standardised diagnostic
interview is performed to assess psychiatric comorbid
disorders in the study participants. Only psychiatric dis-
orders that necessitate a different kind of therapeutic
management are excluded as comorbid disorders. This
reflects the current epidemiological findings on the high
rate of psychiatric comorbid disorders in ASD [4], and
allows secondary analyses on the kind and rate of
comorbid psychiatric disorders and their influence on
therapeutic outcome. Going beyond previous RCTs, not
only children but also adolescents are included, and the
study manual provides specific age-appropriate training
material. Also, children with IQ >= 70 (compared to IQ
> 85) are allowed into the trial, which reflects the clinical
need of many children with ASD. These inclusion cri-
teria are rather broad and may result in a somewhat
smaller effect size of the intervention in the full group
compared to the recently published trials, but also will
allow probing for factors influencing therapy outcome.
Similarly, stable medication is allowed in this trial,
reflecting clinical practices, and again allowing testing of
the influence of the combined treatment on outcome in
secondary analyses.
With regard to study methods, and similar to previous
studies, parent rating (here: the parent- rated social re-
sponsiveness assessed by SRS) was chosen as the pri-
mary outcome measure. This is a critical aspect, as
parents and their children cannot be blinded with regard
to the intervention. Teachers are blind to the allocation
of the ASD individuals to the intervention or control
group. Thus, the present study also aims to obtain as
many teacher-reported SRS data as possible. However,
due to the well known difficulties in obtaining complete
teacher ratings compared to parent ratings, the teacher-
rated SRS was not chosen as a primary outcome meas-
ure. In addition to the primary outcome measure, several
additional secondary outcome measures tapping ASD-
specific behaviour and comorbid anxious and depressive
symptoms, as well neural functional change induced by
therapy, are clearly going beyond the currently published
RCTs on SST in ASD. The automated online randomisa-
tion procedure is clearly defined and reflects the study
design with respect to the multi-centre study and the
group-based randomisation. The statistical analysis also
takes the different study centres into account. A strong
advantage of the current study is the 3 months follow-
up assessment, providing some information on long-
term effects of group-based SST in HFASD.
Finally, the therapeutic approach chosen, combining
child-based SST with parent training to increase the
children’s compliance with the training is a setting that
can be easily implemented in non-university clinical
settings. Compared with the published RCTs (Table 1),
therapeutic frequency is fairly similar with 12-weekly
sessions of 90 minutes of SST. The only exception to the
weekly training sessions was in the very intensive summer
camp treatment program by Lopata et al. (2010), which
provides many more therapy hours, but might be less
cost-effective compared to weekly SST programs that can
also be provided throughout the year. In addition to the
traditional SST in ASD focusing on social rule-based
learning, social understanding and practising of social
skills, the SOSTA-FRA manual also includes executive
function training, anger control strategies, and training of
behavioural and cognitive flexibility overcoming stereo-
typed behaviour and intense special interests interfering
with social interaction. Thereby, it addresses the broad
range of everyday difficulties in children and adolescents
with ASD.
In conclusion, this large multi-centre RCT on the
manualised SOSTA-FRA program addresses a strong
clinical need and will provide further insight into the ef-
ficacy of SST, its moderating factors, and the 3-month
long-term effects of SST in individuals with HFASD.
Trial status
Patient recruitment started on 20 May 2010 and will be
finished in March 2013. Currently (October 2012), 204
patients have been randomised.
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